 Reproductive potential and agrees to follow one of the options listed in the GSK Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of Reproductive Potential FRP, from 30 days prior to the first dose of study medication and until after the last dose of study medication and completion of the follow-up visit at Day 183 at least five terminal half-lives for raxibacumab. 